Mobile

A prospective randomized clinical trial with the medical device Therasphere versus the drug sorafenib for the treatment of liver cancer (HCC) with a clot in the major liver (Portal Vein Thrombosis - P...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005375-14

A prospective randomized clinical trial with the medical device Therasphere versus the drug sorafenib for the treatment of liver cancer (HCC) with a clot in the major liver (Portal Vein Thrombosis - PVT)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of patients with portal vein thrombosis associated with unresectable hepatocellular carcinoma.

Critère d'inclusion

  • Advanced Hepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT)

Liens